Kintara Therapeutics (NASDAQ:KTRA) issued its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03, Fidelity Earnings reports.
KTRA traded up $0.07 during trading on Thursday, hitting $0.89. 66,161 shares of the company’s stock traded hands, compared to its average volume of 1,015,276. The stock has a market capitalization of $28.95 million, a price-to-earnings ratio of -0.41 and a beta of 1.53. The company’s 50 day simple moving average is $1.43 and its two-hundred day simple moving average is $1.58. Kintara Therapeutics has a 12-month low of $0.80 and a 12-month high of $3.35.
KTRA has been the subject of a number of recent research reports. Aegis lowered their price objective on Kintara Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday. Maxim Group reissued a “buy” rating and set a $6.00 price objective on shares of Kintara Therapeutics in a research report on Friday, July 2nd. Finally, HC Wainwright started coverage on shares of Kintara Therapeutics in a research note on Tuesday. They set a “buy” rating and a $6.00 price objective for the company.
Kintara Therapeutics, Inc is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Further Reading: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.